Indaptus Therapeutics, Inc. (INDP) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Indaptus Therapeutics, Inc.'s filing signal turned negative.

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a novel, systemically administered anti-cancer and anti-viral immunotherapy. Its patented technology utilizes attenuated, killed, non-pathogenic Gram-negative bacteria designed to activate both innate and adaptive immune cells, showing broad anti-tumor and anti-viral activity in preclinical models. The company initiated a Phase 1 clinical trial for its lead candidate, Decoy20, in advanced solid tumors, but has since discontinued enrollment in its combination study and has no current plans for new clinical trials. Following a significant investment in December 2025, the company is evaluating strategic transactions, such as acquisitions, to create future growth opportunities.

The company has not generated any revenue from product sales and is currently in the clinical development stage. Future revenue is dependent on the successful development and commercialization of its product candidates.